Effect of total androgen ablation on pathologic stage and resection limit status of prostate cancer. Initial results of the Italian PROSIT study

Pathology Research and Practice

Volumn 195, Issue 4, 1999, Pages 201-208

  Montironi, Rodolfo ^a   Diamanti, Lucilla ^a   Santinelli, Alfredo ^a   Galetti Prayer, Tommaso ^b   Zattoni, Filiberto ^c   Selvaggi, Francesco Paolo ^d   Pagano, Francesco ^b   Bono, Aldo Vittorio ^e  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^d UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^e OSPEDALE DI CIRCOLO   (Italy)

Author keywords

Androgen deprivation; Prostate cancer; Prostatectomy; Surgical margins; Tumour stage

Indexed keywords

ANDROGEN; BICALUTAMIDE; GOSERELIN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISSECTION; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; ITALY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATHOLOGIST; PELVIS LYMPH NODE; PHASE 3 CLINICAL TRIAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL;

EID: 0032891521     PISSN: 03440338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0344-0338(99)80036-3     Document Type: Article

References (39)

1. Abbas F, Scardino PT (1996) Why neoadjuvant androgen deprivation prior to radical prostatectomy is unnecessary. Urol Clin North Am 23: 587-604
2. Algaba F, Boecking A, Bono A, Bostwick DG, Busch C, Di Sant'Agnese PA, Epstein J, Hutter R, Lepinard V, Montironi R, Mostofi FK, Sakamoto A, Sakr WA, Trials I (1997) Prognostic markers in acinar prostate cancer. In: Murphy G, et al (Eds) Proceedings of the First International Consultation on Prostate Cancer, pp 415-423. Scientific Communication International Ltd
3. Armas OA, Aprikian A, Melamed J, Cordon-Cardo C, Cohen DW, Erlandson R, Fair W, Reuter WE (1994) Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy in clinically localized prostatic carcinoma. Am J Surg Pathol 18: 979-991
4. Aus G, Abrahamsson PA, Goran A, Hugosson J, Schain M, Schelin S, Pedersen K (1996) Pretreatment with triptorelin before radical prostatectomy - A 2 year follow-up. Eur Urol 30A (Suppl 2): 209
5. Bazinet M, Zheng W, Begin LR, Aprikian AG, Karakiewicz PI, Elhilali MM (1997) Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma. Urology 49: 721-725
6. Bostwick DG, Myers RP, Oesterling JE (1994) Staging of prostate cancer. Sem Surg Oncol 10: 60-72
7. Catalona WJ, Smith Ds, Ratliff TL, Dodds Km, Coplen De, Yuan JJJ, Petros JA, Andriole GL (1991) Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324: 1156-1161
8. Civantos F, Soloway MS, Pinto JE (1996) Histopathological effects of androgen deprivation in prostatic cancer. Sem Urol Oncol 14 (Suppl 2): 22-31
9. Crawford ED, Eisenburger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321: 419-424
10. Epstein JI, Pizov G, Walsh PC (1993) Correlation of pathological findings with progression after radical retropubic prostatectomy. Cancer 71: 3582-3593
11. Fair WR, Aprikian A, Sogani P, Reuter V, Whitmore WF (1993) The role of neoadjuvant hormonal manipulation in localized prostatic cancer. Cancer 71 (Suppl): 1031-1038
12. Fair WR, Cookson MS, Stroumbakis N, Cohen D, Aprikian AG, Wang Y, Russo P, Soloway SM, Sogani P, Sheinfeld J, Herr H, Dalgabni G, Begg CB, Heston WD, Reuter VE (1997) The indications rationale and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer. Urology 49 (Suppl): 46-55
13. Ferguson J, Zincke H, Ellison E, Bergstrahl E, Bostwick DG (1994) Decrease of prostatic intraepithelial neoplasia (PIN) following androgen deprivation therapy in patients with stage T3 carcinoma treated by radical prostatectomy. Urology 44: 91-95
14. Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Kinahan J, Sullivan LD (1996) Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancer. Sem Urol Oncol 14 (Suppl 2): 39-47
15. Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD (1995) Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinical confined prostate cancer. J Urol 155: 213-219
16. Goldenberg SL, Klotz LH, Jewett MAS, Srigley J, Barkin J, Mador D, Fradet Y, Chin JL, Paquin JM, Laplante S (The Canadian Urologic Oncology Group) (1996) Randomized, controlled study of neoadjuvant reversible androgen withdrawal therapy for prostate cancer. J Urol 156: 873-877
17. Labrie F, Cusan L, Gomez JL, Diamond P, Suburu R, Leenay M, Tetu B, Fradet Y, Gansas B (1994) Downstaging of early stage prostate cancer before radical prostatectomy: The first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing agonist. Urology 44: 29-37
18. Magi Galluzzi C, Montironi R, Giannulis I, Diamanti L, Scarpelli M (1993) Prostatic invasive adenocarcinoma. Effect of combination endocrine therapy (LHRH agonist and flutamide) on the expression and location of Proliferating Cell Nuclear Antigen (PCNA). Path Res Pract 189: 1154-1160
19. Montironi R, Magi Galluzzi C, Fabris G (1995) Apoptotic bodies in prostatic intraepithelial neoplasia and prostatic adenocarcinoma following total androgen ablation. Path Res Pract 191: 873-880
20. Montironi R, Magi Galluzzi C, Muzzonigro G, Prete E, Polito M, Fabris G (1994) Effect of Combination Endocrine Therapy (LHRH agonist and flutamide) on normal prostate, Prostatic Intraepithelial Neoplasia and prostatic adenocarcinoma. J Clin Pathol 47: 906-913
21. Montironi R, Magi Galluzzi C, Scarpelli M, Diamanti L (1994) Quantitative characterisation of the frequency and location of cell proliferation and death in prostate pathology. J Cell Biochem 19 (Suppl): 238-245
22. Murphy WM, Soloway MS, Barrows GH (1991) Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer 68: 821-828
23. Ohori M, Wheeler TM, Kattan MW et al. (1995) Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 154: 1818-1824
24. Pagano F., Bono A., Zattoni F., Montironi R., Prayer Galetti T on behalf of the PROSIT Study Group: Neoadjuvant Hormonal Therapy before surgery for prostate cancer. The Italian experience: PROSIT Study. Molecular Urology (in press)
25. Paulson DF (1994) Impact of radical prostatectomy in the management of clinically localized disease. J Urol 152: 1826-1830
26. Reuter VE (1997) Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology 49 (Suppl 3A) 16-22
27. Schulman CC (1994) Neoadjuvant androgen blockade prior to prostatectomy: a retrospective study and critical review. Prostate 5 (Suppl): 9-13
28. Schulman CC, Sassine AM (1993). Neoadjuvant hormonal deprivation before radical prostatectomy. Eur Urol 24: 450-455
29. Schulman CC, Wildschutz T, Zlotta AR (1997) Neoadjuvant hormonal treatment prior to radical prostatectomy: facts and questions. Eur Urol 32 (Suppl): 41-47
30. Smith DM, Murphy WM (1994) Histologic changes in prostate carcinomas treated with Leuprolide (Luteinizing Hormone-releasing Hormone effect). Distinction from poor tumor differentiation. Cancer 73: 1472-1477
31. Soloway MS, Sharifi R, Wood D, Wajsman Z, McLeod D, Puras A (1995) Randomized comparison of radical prostatectomy alone or preceded by androgen deprivation for cT2 prostate cancer. J Urol 154: 424-428
32. Tetu B, Srigley JR., Boivin J-C, Dupont A, Monfette G, Pinault S, Labrie F (1991) Effect of combination endocrine therapy (LHRH agonist and flutamide) on normal prostate and prostatic adenocarcinoma. Am J Surg Pathol 75: 111-120
33. Trachtenberg J (1996) Neoadjuvant androgen ablation therapy prior to radical prostatectomy: quantum leap or hope unrealised? Curr Opin Urol 6: 254-257
34. Vaillancourt L, Tetu B, Fradet Y, Dupont A, Gomez J, Cusan L, Suburu ER, Diamond P, Candas B, Labrie F (1996) Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. J Surg Pathol 20: 86-93
35. Watson RB, Soloway MS (1996) Neoadjuvant hormonal treatment before radical prostatectomy. Seminars Urol Oncol 14 (Suppl 2):48-56
36. Wieder JA, Soloway MS (1998) Incidence, etiology, location, prevention and treatment pf positive surgical margins after radical prostatectomy for prostate cancer. J Urol 160: 299-315
37. Witjes WPJ, Oosterhof GON, Schaafsma HE, Debruyne FMJ (1995) Current status of neoadjuvant therapy in localized prostate cancer. Prostate 27: 297-303
38. Witjes WPJ, Schulman CC, Forster G, Debruyne F, Van Cangh P, Cesare A (1996) European Study Group on Neoadjuvant Treatment. Eur Urol 30 (Suppl 2): 210
39. Wojno KJ, Epstein JI (1995) The utility of basal cell-specific anti-cytokeratin antibody (34 beta E 12) in the diagnosis of prostate cancer. A review of 228 cases. Am J Surg Pathol 19: 251-260